Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥5,427 JPY
Change Today +58.00 / 1.08%
Volume 2.0M
As of 2:00 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - ¥6,657
52 Week Low
10/17/14 - ¥4,338
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, central nervous system, immunology and respiratory, general medicine, oncology, gastroenterology, and vaccines. The company has a partnership with Gencia LLC to develop a class of small molecule drugs as potential treatments for hematological and inflammatory diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Senior Vice Preside...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Obtains New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe

Takeda Pharmaceutical Company Limited obtained the New Drug Application approval for Copaxone® Subcutaneous Injection 20 mg Syringe, a drug for the treatment of multiple sclerosis, from the Japanese Ministry of Health, Labour and Welfare. Developed by Teva Pharmaceutical Industries Ltd., Copaxone® is a subcutaneous injection administered once daily to prevent the relapse of multiple sclerosis. Copaxone® is one of the most frequently-used drugs in multiple sclerosis therapy and is approved in more than 50 countries worldwide. In Japan, glatiramer acetate was developed as an Unapproved New Drug by Teva Pharmaceutical K.K., at the request of the Japanese Ministry of Health, Labour and Welfare. In March, 2013, Takeda and Teva signed a licensing agreement in which Teva granted Takeda the right to commercialize glatiramer acetate in Japan. Takeda submitted thex NDA in December 2014 under the terms of this agreement. The approval is based on the safety and efficacy results of an open-label, 52-week clinical trial conducted in Japan by Teva Pharmaceutical K.K. in patients with relapsing-remitting multiple sclerosis as well as 3 clinical trials from overseas conducted by Teva in patients with relapsing-remitting multiple sclerosis.

Takeda Pharmaceutical Company Limited Presents at FT Latin America Healthcare and Life Sciences Conference 2015, Sep-29-2015 02:05 PM

Takeda Pharmaceutical Company Limited Presents at FT Latin America Healthcare and Life Sciences Conference 2015, Sep-29-2015 02:05 PM. Venue: Viceroy Miami, 485 Brickell Avenue, Miami, FL 33131, United States. Speakers: Ricardo Marek, Area Head of LATAM and General Manager, Brazil.

Gencia LLC and Takeda Pharmaceutical Company Limited Announces Partnership to Develop New Class of Small Molecule Drugs as Potential Treatments for Hematological and Inflammatory Diseases

Gencia LLC and Takeda Pharmaceutical Company Limited announced a partnership to develop a new class of small molecule drugs as potential treatments for hematological and inflammatory diseases. Called Mitochondrial Agonists of the Glucocorticoid Receptor (MAGR), such compounds may offer the therapeutic potential of conventional glucocorticoid drugs (steroids). However, MAGR are chemically distinct and may function differently than steroids. The initial aim of the collaboration will be joint research and development leading to two preclinical drug candidates, one each in the areas of inflammation and oncology. Takeda will explore opportunities to conduct clinical trials for drug candidates identified by the partnership. Under the agreement, Gencia will receive upfront payments and preclinical milestones for the two compounds and aggregate clinical, commercialization and sales milestones with the potential for approximately $500 million in payments by Takeda. Gencia also will receive royalties on sales of any successfully commercialized products arising from the partnership. Further details of the agreement were not disclosed. Glucocorticoid drugs are used in front-line, combination, maintenance and relapse therapy in the treatment of many hematological and inflammatory diseases. However, side-effects, lack of response or induced resistance frequently limit glucocorticoid use. Gencia’s MAGR agonists have shown activity in numerous steroid-sensitive and steroid-resistant pharmacology models. Gencia and Takeda will explore potential therapeutic uses of MAGRs and the possibilities for their safe and effective chronic use.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥5,427.00 JPY +58.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.39 USD +0.01
Baxter International Inc $33.30 USD -0.25
Becton Dickinson and Co $136.99 USD +1.62
Biogen Inc $286.55 USD -3.80
Merck KGaA €79.52 EUR +0.045
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 2.0x
Price/Cash Flow 177.4x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at